Who Paid My Doc
Tetraphase Pharmaceuticals, Inc.
MA, United States
CMS manufacturer 100000391810
General payments
$813,313
Research payments
$750,952
Ownership & investment interest
$0
Through program year 2025, Tetraphase Pharmaceuticals, Inc. reported paying $813,313 in general payments and $750,952 in research payments to U.S. physicians, teaching hospitals and other recipients.
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
9 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $6,849 | 306 |
| 2025 | Research | $167,820 | 19 |
| 2023 | General | $11,613 | 3 |
| 2022 | Research | $16,898 | 15 |
| 2021 | Research | $106,807 | 58 |
| 2020 | General | $96,312 | 865 |
| 2020 | Research | $229,579 | 72 |
| 2019 | General | $698,539 | 3,734 |
| 2019 | Research | $229,849 | 54 |
Breakdown
Each share is of this company’s general payments naming a product in 2025. A payment can name up to five products, so these amounts overlap.
The top 5 of 19 specialties; each share is of this company’s general payments to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 23 states; each share is of this company’s general payments in 2025 where a state was reported.
Records
4,908 general · 218 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers of drugs, devices and biologicals, and group purchasing organisations, are required to report the payments and transfers of value they make to physicians and teaching hospitals. This page shows what this company reported.